Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Risk Management Overview (Tables)

Risk Management Overview (Tables)

12 Months Ended

Mar. 31, 2023

Disclosure of risk management strategy related to hedge accounting [abstract]

Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies Explanatory

As at March 31, 2023 and 2022, the Company had the following monetary assets and liabilities denominated in foreign currencies:


		As of March 31,
		2023				2022
		RMB				RMB
Cash			16,667				172
AP and Accrual Liabilities			(209,270	)			(26,768	)

		As of March 31,
		2023				2022
		GBP				GBP
Cash			2,421,553				—
AP and Accrual Liabilities			(46,506	)			—

		As of March 31,
		2023				2022
		SGD				SGD
Cash			63,141				904
AP and Accrual Liabilities			(8,361	)			—